AccuMetab™ Human CYP1A2 Enzyme, Catalytically Active

CAT#: ITS-0426-YL1
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP1A2 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Cytochrome P450 1A2 is a major hepatic enzyme responsible for the clearance of approximately 9% of marketed drugs, including caffeine and clozapine. It is highly inducible by polycyclic aromatic hydrocarbons and tobacco smoke, making it a critical target for evaluating specific drug-drug interactions and procarcinogen activation.
Key Features
Proprietary E. coli expression; High and low reductase ratio options; Validated for caffeine and phenacetin clearance; Ideal for procarcinogen activation screening
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME, Drug-Drug Interactions (DDI), Toxicology
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry